SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

APN sets FY 2027 targets: ZAR 9bn+ EBITDA and 50%+ NHEPS growth

Aspen Pharmacare says it delivered strong EBITDA and NHEPS growth despite flat revenue. It targets FY 2027 EBITDA over ZAR 9 billion, 50%+ NHEPS growth, and robust free cash flow, prioritizing share buybacks.

APN

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories